Compare UMBF & NUVL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | UMBF | NUVL |
|---|---|---|
| Founded | 1913 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.4B | 7.8B |
| IPO Year | 2006 | 2021 |
| Metric | UMBF | NUVL |
|---|---|---|
| Price | $109.13 | $96.49 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 15 |
| Target Price | ★ $140.20 | $135.33 |
| AVG Volume (30 Days) | ★ 468.7K | 444.2K |
| Earning Date | 04-28-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.54% | N/A |
| EPS Growth | ★ 3.34 | N/A |
| EPS | ★ 9.29 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $18.03 | N/A |
| Revenue Next Year | $6.55 | $1,165.56 |
| P/E Ratio | $12.03 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $82.00 | $55.54 |
| 52 Week High | $136.11 | $113.02 |
| Indicator | UMBF | NUVL |
|---|---|---|
| Relative Strength Index (RSI) | 35.23 | 41.51 |
| Support Level | $105.42 | $73.71 |
| Resistance Level | $113.20 | $107.13 |
| Average True Range (ATR) | 2.74 | 3.10 |
| MACD | 0.33 | -0.07 |
| Stochastic Oscillator | 26.11 | 24.25 |
UMB Financial Corp, or UMBF, is a financial services holding company offering a suite of banking services and asset servicing to its customers in the United States and around the world. Its client base includes commercial, institutional, and personal customers. Along with its subsidiaries, the company operates in the following business segments: Commercial Banking, Institutional Banking, and Personal Banking. A majority of its revenue is generated from the Commercial Banking segment, which serves the commercial banking and treasury management needs of small to middle-market businesses through various products and services such as commercial loans, commercial real estate financing, commercial credit cards, letters of credit, loan syndication services, consultative services, and others.
Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of its operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.